<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<title>Hyperglycemic Hyperosmolar State (HHS) ‚Äì Collapsible Guide (US units)</title>
<style>
  :root{
    --bg:#f7fbff;
    --card:#ffffff;
    --ink:#13233a;
    --muted:#4b5b70;
    --accent:#0b6aa8;
    --accentSoft:#e7f3ff;
    --border:#d6e2ef;
    --danger:#b42318;
    --warn:#b45309;
    --shadow:0 6px 18px rgba(16,24,40,.08);
    --radius:16px;
    --mono: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
  }
  *{box-sizing:border-box}
  body{
    margin:0;
    font-family: system-ui, -apple-system, Segoe UI, Roboto, Arial, sans-serif;
    background: radial-gradient(circle at 10% 0%, #eef7ff 0%, var(--bg) 45%, #ffffff 100%);
    color:var(--ink);
    line-height:1.45;
  }
  header{
    padding:18px 16px 10px;
    position:sticky; top:0;
    background: rgba(247,251,255,.88);
    backdrop-filter: blur(8px);
    border-bottom:1px solid var(--border);
    z-index:5;
  }
  .topbar{
    max-width:1000px;
    margin:0 auto;
    display:flex;
    gap:10px;
    align-items:center;
    justify-content:space-between;
    flex-wrap:wrap;
  }
  .titlewrap{ display:flex; align-items:baseline; gap:10px; flex-wrap:wrap; }
  h1{ font-size:20px; margin:0; letter-spacing:.2px; }
  .subtitle{ color:var(--muted); font-size:13px; }
  .nav{ display:flex; gap:8px; flex-wrap:wrap; }
  .btn{
    display:inline-flex; align-items:center; gap:8px;
    padding:10px 12px;
    border:1px solid var(--border);
    border-radius:999px;
    background:var(--card);
    color:var(--ink);
    text-decoration:none;
    box-shadow: 0 2px 8px rgba(16,24,40,.06);
    font-size:13px;
  }
  .btn:hover{ border-color:#b7cee6; transform: translateY(-1px); }
  main{ padding:18px 16px 40px; }
  .container{ max-width:1000px; margin:0 auto; }
  .card{
    background:var(--card);
    border:1px solid var(--border);
    border-radius:var(--radius);
    box-shadow:var(--shadow);
    padding:16px;
    margin:14px 0;
  }
  .note{
    background:#fff7ed;
    border:1px solid #fed7aa;
    color:#7c2d12;
    border-radius:14px;
    padding:12px 14px;
    font-size:13px;
  }
  .pill{
    display:inline-block;
    padding:4px 10px;
    border-radius:999px;
    background:var(--accentSoft);
    border:1px solid #cfe6ff;
    color:var(--accent);
    font-size:12px;
    margin-right:6px;
    white-space:nowrap;
  }
  details{
    border:1px solid var(--border);
    border-radius:14px;
    background:#fbfdff;
    margin:10px 0;
    overflow:hidden;
  }
  summary{
    cursor:pointer;
    list-style:none;
    padding:12px 14px;
    display:flex;
    align-items:center;
    justify-content:space-between;
    gap:10px;
    font-weight:650;
  }
  summary::-webkit-details-marker{ display:none; }
  .chev{
    width:26px; height:26px;
    border-radius:999px;
    border:1px solid var(--border);
    display:grid; place-items:center;
    background:var(--card);
    flex:0 0 auto;
  }
  details[open] .chev{ transform: rotate(180deg); }
  .content{ padding: 0 14px 14px; }
  .content p{ margin:10px 0; }
  .content ul{ margin:8px 0 8px 18px; }
  .content li{ margin:6px 0; }
  .muted{ color:var(--muted); }
  .mono{ font-family: var(--mono); }
  .grid{
    display:grid;
    grid-template-columns: 1fr;
    gap:12px;
  }
  @media (min-width: 900px){
    .grid{ grid-template-columns: 1fr 1fr; }
  }
  .mini-card{
    border:1px dashed #cfe0f2;
    background:#ffffff;
    border-radius:14px;
    padding:12px 12px;
  }
  .tbl{
    width:100%;
    border-collapse: collapse;
    overflow:hidden;
    border-radius:12px;
    border:1px solid var(--border);
    background:#fff;
    margin-top:10px;
  }
  .tbl th, .tbl td{
    border-bottom:1px solid var(--border);
    padding:10px 10px;
    font-size:13px;
    vertical-align:top;
  }
  .tbl th{
    text-align:left;
    background:var(--accentSoft);
    color:var(--accent);
    font-weight:700;
  }
  .figure{
    border:1px dashed #b9d7f5;
    background:#f4f9ff;
    border-radius:14px;
    padding:12px;
    margin:12px 0;
  }
  .figure strong{ color:var(--accent); }
  .figure img{
    width:100%;
    height:auto;
    border-radius:12px;
    border:1px solid #cfe6ff;
    background:#fff;
    display:block;
    margin-top:10px;
  }
  .small{ font-size:12.5px; color:var(--muted); }
  .anchorlinks{
    max-width:1000px;
    margin:10px auto 0;
    display:flex; flex-wrap:wrap; gap:8px;
  }
  .anchorlinks a{
    font-size:12.5px;
    color:var(--accent);
    text-decoration:none;
    border:1px solid #cfe6ff;
    background:#ffffff;
    padding:7px 10px;
    border-radius:999px;
  }
  .anchorlinks a:hover{ background:var(--accentSoft); }
  .badge{
    display:inline-block;
    padding:3px 8px;
    border-radius:999px;
    font-size:12px;
    border:1px solid var(--border);
    background:#fff;
    color:var(--ink);
    white-space:nowrap;
  }
  .badge-danger{ border-color:#fecaca; background:#fee2e2; color:#7f1d1d; }
  .badge-warn{ border-color:#fed7aa; background:#fff7ed; color:#7c2d12; }
  footer{
    padding:18px 16px 30px;
    color:var(--muted);
    text-align:center;
  }
</style>
</head>
<body>

<header>
  <div class="topbar">
    <div class="titlewrap">
      <h1>Hyperglycemic Hyperosmolar State (HHS)</h1>
    </div>
    <div class="nav">
      <a class="btn" href="../index.html">üè† Home</a>
      <a class="btn" href="../endocrine.html">‚Ü©Ô∏é Back to Endocrine</a>
    </div>
  </div>

  <div class="anchorlinks">
    <a href="#def">Definition</a>
    <a href="#epi">Epidemiology</a>
    <a href="#path">Pathophysiology</a>
    <a href="#precip">Precipitants</a>
    <a href="#features">Clinical features</a>
    <a href="#dx">Diagnosis</a>
    <a href="#invest">Investigations</a>
    <a href="#mgmt">Management</a>
    <a href="#severity">Severity</a>
    <a href="#fluids">IV fluids</a>
    <a href="#insulin">Insulin</a>
    <a href="#elect">Electrolytes</a>
    <a href="#monitor">Monitoring</a>
    <a href="#targets">Targets</a>
    <a href="#care">Continuing care</a>
    <a href="#comp">Complications</a>
  </div>
</header>

<main>
  <div class="container">


    <div class="card" id="def">
      <span class="pill">Definition & classification</span>
      <p>
        Hyperglycaemic hyperosmolar state (HHS) is an acute diabetic emergency that occurs in patients with type 2 diabetes mellitus.
        HHS occurs insidiously over several days with dehydration and metabolic disturbances that are more extreme than diabetic ketoacidosis (DKA).
      </p>

      <details open>
        <summary>Characteristic features <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <ul>
            <li><strong>Hypovolaemia</strong></li>
            <li><strong>Hyperglycaemia</strong>: <span class="mono">&gt; 540 mg/dL (&gt; 30 mmol/L)</span></li>
            <li><strong>Mild or absent ketonaemia</strong>: <span class="mono">blood ketones &lt; 3 mmol/L</span></li>
            <li><strong>High osmolality</strong>: <span class="mono">&gt; 320 mOsm/kg</span></li>
          </ul>
          <p>
            HHS is clinically distinct to DKA and requires a different approach to treatment. Patients are usually elderly with multiple co-morbidities, and as a result may be very unwell.
          </p>
        </div>
      </details>

      <p class="small">
        Previously termed <em>Hyperglycaemic Hyperosmolar Non-ketotic Coma (HONK)</em>. Terminology changed as most patients do not present in coma, though they may be extremely unwell.
      </p>
    </div>

    <div class="card" id="epi">
      <span class="pill">Epidemiology</span>
      <p>
        HHS is a life-threatening condition, which usually occurs in the elderly but is increasingly recognised in younger patients.
      </p>
      <ul>
        <li>Estimated to account for ~1% of diabetic hospital admissions.</li>
        <li>Average age of presentation ~60 years.</li>
        <li>Associated with <strong>15‚Äì20% mortality</strong>.</li>
        <li>Often the first presentation of type 2 diabetes mellitus in up to 20‚Äì30% of cases.</li>
      </ul>
    </div>

    <div class="card" id="path">
      <span class="pill">Pathophysiology</span>

      <details open>
        <summary>Mechanism<span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            In HHS, the relative lack of insulin is coupled with a rise in counter-regulatory hormones (e.g. cortisol, growth hormone, glucagon) that leads to a profound rise in glucose.
            These patients retain a certain level of insulin, which prevents the development of ketosis that epitomises DKA.
            However, the level of insulin is inadequate to prevent profound hyperglycaemia.
          </p>
          <p>
            The excessive glucose leads to massive osmotic diuresis within the kidneys with the loss of essential electrolytes such as sodium and potassium.
            This is because the proximal tubules within the kidneys only have a certain capacity for reabsorption of glucose. Once this is reached, the remaining glucose is passed through the renal nephrons causing diuresis.
          </p>
          <p>
            As water is lost, there is profound dehydration and reduced circulating volume, resulting in hyperosmolarity and marked hyperglycaemia.
            Patients with HHS may have up to a 9 litre deficit of water.
          </p>
          <p>
            Increased osmolality triggers compensatory mechanisms (ADH release and thirst), but if these cannot compensate (e.g. elderly patients with co-morbidities),
            hypovolaemia develops with progression to acute kidney injury, electrolyte disturbances, hypotension and coma.
          </p>
          <p>
            The hyperosmolar state leads to hyperviscosity, increasing the risk of arterial and venous thrombosis (e.g. stroke, DVT).
          </p>

          <div class="figure">
            <strong>HHS pathophysiology</strong>
            <img src="images/hhs_pathophysiology.jpg" alt="HHS pathophysiology diagram (placeholder)" />
          </div>
        </div>
      </details>
    </div>

    <div class="card" id="precip">
      <span class="pill">Precipitants</span>
      <p class="muted">A number of underlying conditions are known to precipitate HHS (many cases are new T2DM diagnoses).</p>
      <ul>
        <li>Infection</li>
        <li>High-dose steroids</li>
        <li>Myocardial infarction</li>
        <li>Vomiting</li>
        <li>Stroke</li>
        <li>Poor treatment concordance</li>
      </ul>
    </div>

    <div class="card" id="features">
      <span class="pill">Clinical features</span>

      <details open>
        <summary>Symptoms & signs <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            Onset is usually insidious with dehydration over days to weeks. Early features may include polyuria, polydipsia and nausea;
            late features include altered mental status, seizures and possibly coma.
          </p>

          <div class="grid">
            <div class="mini-card">
              <strong>Symptoms</strong>
              <ul>
                <li>Polydipsia</li>
                <li>Polyuria</li>
                <li>Nausea</li>
                <li>Vomiting</li>
                <li>Muscle cramps</li>
                <li>Weakness</li>
                <li>Altered mental status</li>
                <li>Seizures</li>
                <li>Coma</li>
              </ul>
            </div>
            <div class="mini-card">
              <strong>Signs</strong>
              <ul>
                <li>Dehydration (dry mucous membranes, sunken eyes, reduced capillary refill, decreased skin turgor)</li>
                <li>Hypotension</li>
                <li>Decreased urine output</li>
                <li>Decreased conscious level</li>
                <li>Coma</li>
                <li>Focal neurology signs</li>
                <li>Features of precipitating cause</li>
              </ul>
            </div>
          </div>

          <div class="figure">
            <strong>HHS symptoms/signs</strong>
            <img src="images/hhs_features.jpg" alt="HHS clinical features image (placeholder)" />
          </div>
        </div>
      </details>
    </div>

    <div class="card" id="dx">
      <span class="pill">Diagnosis</span>

      <details open>
        <summary>Diagnostic criteria (take in clinical context) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            Diagnosis is based on marked hyperglycaemia, raised serum osmolality, and mild/absent ketonaemia,
            interpreted in context of the patient‚Äôs clinical state (i.e. hypovolaemia/dehydration).
          </p>

          <table class="tbl">
            <thead>
              <tr><th>Parameter</th><th>Threshold</th></tr>
            </thead>
            <tbody>
              <tr><td>Laboratory glucose</td><td class="mono">&gt; 540 mg/dL (&gt; 30 mmol/L)</td></tr>
              <tr><td>Serum osmolality</td><td class="mono">&gt; 320 mOsm/kg</td></tr>
              <tr><td>Ketones (urine)</td><td class="mono">Negative / trace / 1+</td></tr>
              <tr><td>Ketones (blood)</td><td class="mono">&lt; 3 mmol/L</td></tr>
            </tbody>
          </table>

          <details>
            <summary>Osmolality formulas<span class="chev">‚åÑ</span></summary>
            <div class="content">
              <p class="muted">If measured plasma osmolality isn‚Äôt available, use a calculated surrogate.</p>

              <div class="mono">Calculated osmolality ‚âà 2√óNa (mEq/L) + Glucose/18 + BUN/2.8</div>

            </div>
          </details>
        </div>
      </details>
    </div>

    <div class="card" id="invest">
      <span class="pill">Investigations</span>

      <details open>
        <summary>Key + additional investigations <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p class="muted">Key tests: glucose, urea & electrolytes, blood gas (VBG/ABG), and blood or urinary ketones.</p>

          <div class="grid">
            <div class="mini-card">
              <strong>Bedside tests</strong>
              <ul>
                <li>ECG</li>
                <li>Urinalysis ¬± MSU/urine culture</li>
                <li>Urinary pregnancy test (as indicated)</li>
              </ul>
            </div>
            <div class="mini-card">
              <strong>Blood tests</strong>
              <ul>
                <li>FBC/CBC</li>
                <li>U&Es/BMP/CMP</li>
                <li>CRP</li>
                <li>LFTs</li>
                <li>Blood cultures</li>
                <li>Troponin</li>
                <li>Amylase</li>
                <li>CK</li>
              </ul>
            </div>
          </div>

          <div class="mini-card" style="margin-top:12px;">
            <strong>Imaging</strong>
            <ul>
              <li>Chest X-ray</li>
              <li>CT head (if reduced GCS or focal neurology)</li>
            </ul>
          </div>
        </div>
      </details>
    </div>

    <div class="card" id="mgmt">
      <span class="pill">Management</span>

      <details open>
        <summary>Core goals <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p class="muted">Management facets: aggressive fluid resuscitation plus normalization of glucose and osmolality.</p>
          <ul>
            <li>Normalise osmolality</li>
            <li>Normalise blood glucose</li>
            <li>Replace fluid and electrolytes</li>
            <li>Prevention of arterial/venous thrombosis</li>
            <li>Prevention of complications & foot ulceration</li>
          </ul>

          <div class="figure">
            <strong>HHS management algorithm</strong>
            <img src="images/hhs_management.jpg" alt="HHS management flowchart (placeholder)" />
          </div>
        </div>
      </details>

      <details>
        <summary>Initial assessment (ABCDE) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p class="muted">All patients should undergo ABCDE assessment with formal GCS and full observations.</p>
          <ul>
            <li>IV access (x2 large-bore cannula)</li>
            <li>Blood/urinary ketones</li>
            <li>Capillary & plasma blood glucose</li>
            <li>CBC, electrolytes (BMP/CMP), venous blood gas, plasma osmolality</li>
            <li>Blood cultures</li>
            <li>Urinalysis ¬± MSU, pregnancy test (as indicated)</li>
            <li>ECG</li>
            <li>CXR</li>
            <li>Urinary catheter (for accurate monitoring when needed)</li>
            <li>Additional tests as indicated (e.g. troponin, CT head)</li>
          </ul>
        </div>
      </details>
    </div>

    <div class="card" id="severity">
      <span class="pill">Severity</span>

      <details open>
        <summary>Markers of severity (higher level of care) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            Patients with HHS are often elderly with multiple co-morbidities and can be extremely unwell. Ideally, manage in a high-dependency environment (level 2 care and above).
          </p>
          <p class="muted">Markers that warrant high-level care:</p>
          <ul>
            <li>Osmolality <span class="mono">&gt; 350 mOsm/kg</span></li>
            <li>Sodium <span class="mono">&gt; 160 mEq/L (160 mmol/L)</span></li>
            <li>pH <span class="mono">&lt; 7.1</span></li>
            <li>GCS <span class="mono">&lt; 12</span></li>
            <li>Systolic BP <span class="mono">&lt; 90 mmHg</span></li>
            <li>Serum creatinine <span class="mono">&gt; 2.26 mg/dL (&gt; 200 Œºmol/L)</span></li>
            <li>Macrovascular event (e.g., MI, CVA)</li>
            <li>Severe electrolyte abnormalities (e.g., hyper/hypokalaemia)</li>
          </ul>
        </div>
      </details>
    </div>

    <div class="card" id="fluids">
      <span class="pill">Intravenous fluids</span>

      <details open>
        <summary>Fluid strategy (slow correction) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            Patients with HHS can have a tremendous fluid deficit. Initial management requires fluid resuscitation to restore circulating volume.
            Initial fluid of choice is <strong>0.9% sodium chloride (normal saline)</strong>; give at least 1 liter over 1 hour (faster if significant hypotension).
          </p>
          <p>
            Further fluids are guided by urine output and clinical response. A proposed target is <span class="mono">+2‚Äì3 liters</span> by 6 hours.
          </p>
          <p>
            Normal saline may cause a transient rise in sodium; if osmolality is falling appropriately this is not an indication for hypotonic saline (e.g., 0.45%).
            Rapid correction is not advisable because of osmolar shifts leading to cerebral oedema ‚Äî generally aim for around <span class="mono">+4 liters</span> in the first 24 hours.
          </p>
        </div>
      </details>
    </div>

    <div class="card" id="insulin">
      <span class="pill">Insulin therapy</span>

      <details open>
        <summary>When to start insulin (delayed and selective) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            Insulin use in HHS should be led by a specialist or senior clinician with experience of HHS management.
          </p>
          <ul>
            <li>Start insulin only if there is evidence of significant ketonaemia (<span class="mono">&gt; 1 mmol/L</span>) or ketonuria (<span class="mono">2+</span> or more).</li>
            <li>Another indication is when glucose is falling less than <span class="mono">90 mg/dL/hr (5 mmol/L/hr)</span>.</li>
            <li>Assess and ensure adequate fluid balance before prescribing insulin.</li>
          </ul>

          <details>
            <summary>Fixed-rate IV insulin infusion (FRIII concept) <span class="chev">‚åÑ</span></summary>
            <div class="content">
              <ul>
                <li>If indicated: FRIII at <span class="mono">0.05 units/kg/hr</span> (half the dose used in DKA).</li>
                <li>Maintain glucose between <span class="mono">180‚Äì270 mg/dL (10‚Äì15 mmol/L)</span> in the first 24 hours.</li>
                <li>Use 5% or 10% dextrose if levels fall <span class="mono">252 mg/dL (14 mmol/L)</span>.</li>
              </ul>
            </div>
          </details>

          <div class="note" style="margin-top:12px;">
            <strong>Practical warning (why the delay matters):</strong>
            In HHS, rapid glucose reduction can drive a rapid drop in plasma osmolality ‚Üí <span class="badge badge-danger">cerebral oedema risk</span>.
            Fluids are the primary therapy early.
          </div>
        </div>
      </details>
    </div>

    <div class="card" id="elect">
      <span class="pill">Electrolyte replacement</span>

      <details open>
        <summary>Electrolytes + potassium rules <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>
            Electrolytes including sodium, potassium, phosphate and magnesium should be monitored regularly (minimum q4h) and replaced as necessary.
            Potassium is especially important if insulin is started, because insulin drives potassium intracellularly ‚Üí low plasma potassium ‚Üí dangerous arrhythmias.
          </p>

          <table class="tbl">
            <thead><tr><th>Serum K‚Å∫</th><th>General rule</th></tr></thead>
            <tbody>
              <tr><td class="mono">&gt; 5.5 mEq/L (mmol/L)</td><td>Nil potassium replacement</td></tr>
              <tr><td class="mono">3.5‚Äì5.5 mEq/L (mmol/L)</td><td>40 mmol potassium replacement</td></tr>
              <tr><td class="mono">&lt; 3.5 mEq/L (mmol/L)</td><td>Senior review for more invasive potassium replacement</td></tr>
            </tbody>
          </table>

          <p class="small">
            Potassium administration concentration/rate depends on peripheral vs central access and renal function (follow hospital protocol).
          </p>
        </div>
      </details>
    </div>

    <div class="card" id="monitor">
      <span class="pill">Monitoring</span>

      <details open>
        <summary>Monitoring schedule and safety checks <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>Patients should be on cardiac monitoring and assessed at regular intervals.</p>
          <ul>
            <li>Every hour: blood glucose, urea & electrolytes, and laboratory or calculated plasma osmolality for first 6 hours.</li>
            <li>If satisfactory fall in osmolality (3‚Äì8 mOsm/kg/hr) and glucose (‚â• 5 mmol/L/hr), blood sampling can be reduced to 2-hourly.</li>
            <li>Maintain accurate fluid balance; urine output documented hourly.</li>
            <li>As parameters improve: reduce to 4-hourly, then 12-hourly monitoring.</li>
            <li>Continuously assess for complications (stroke, DVT, cerebral oedema) and treat precipitant (infection, MI, etc.).</li>
          </ul>
        </div>
      </details>
    </div>

    <div class="card" id="targets">
      <span class="pill">Metabolic treatment targets</span>

      <details open>
        <summary>Targets (what ‚Äúgood progress‚Äù looks like) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <p>Two main metabolic treatment targets should be achieved:</p>
          <ul>
            <li><strong>Plasma osmolality:</strong> falling by <span class="mono">3‚Äì8 mOsm/kg/hr</span></li>
            <li><strong>Blood glucose:</strong> falling by at least <span class="mono">90 mg/dL/hr (5 mmol/L/hr)</span></li>
          </ul>
        </div>
      </details>
    </div>

    <div class="card" id="care">
      <span class="pill">Continuing care</span>

      <details open>
        <summary>Specialist involvement + prevention steps <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <ul>
            <li>Inform specialist diabetes team; ideally assess within 24 hours.</li>
            <li>Start prophylactic LMWH unless contraindicated (high thrombotic risk).</li>
            <li>Regular foot assessment for ulceration; encourage early mobilization; remove catheter when appropriate.</li>
            <li>After initial phase: minimum daily urinalysis, electrolytes, and regular capillary glucose.</li>
            <li>Ongoing need for FRIII vs transition to SQ insulin is managed with specialist team.</li>
            <li>If FRIII started: do not stop until glucose is within target and patient is over acute episode.</li>
            <li>If still not tolerating oral intake: may convert to VRIII in interim period (per institutional protocol).</li>
          </ul>
        </div>
      </details>
    </div>

    <div class="card" id="comp">
      <span class="pill">Complications</span>

      <details open>
        <summary>Major complications (disease + treatment related) <span class="chev">‚åÑ</span></summary>
        <div class="content">
          <ul>
            <li>
              <strong>Myocardial infarction:</strong> hypovolaemia, hyperviscosity and severe illness strain the heart (often with pre-existing CAD).
            </li>
            <li>
              <strong>Thrombotic complications:</strong> hyperviscosity + hypovolaemia predispose to DVT, PE, stroke. Prophylactic LMWH reduces risk if no contraindications.
            </li>
            <li>
              <strong>Cerebral oedema:</strong> may occur from rapid correction of hyperglycaemia with rapid fall in plasma osmolarity ‚Üí headache, reduced GCS, and untreated can lead to death.
            </li>
          </ul>
        </div>
      </details>
    </div>


        <div class="container">

        <div class="card">
        <span class="pill">DKA vs HHS, at a glance</span>
        <table class="tbl">
        <thead>
        <tr><th>Feature</th><th>DKA</th><th>HHS</th></tr>
        </thead>
        <tbody>
        <tr>
        <td>Typical diabetes</td>
        <td>Type 1 (also T2DM)</td>
        <td>Type 2</td>
        </tr>
        <tr>
        <td>Onset</td>
        <td>Hours‚Äì1‚Äì2 days</td>
        <td>Days‚Äìweeks</td>
        </tr>
        <tr>
        <td>Glucose</td>
        <td class="mono">&gt; 200 mg/dL (&gt; 11 mmol/L)</td>
        <td class="mono">&gt; 540 mg/dL (&gt; 30 mmol/L)</td>
        </tr>
        <tr>
        <td>Ketones</td>
        <td class="mono">‚â• 3 mmol/L</td>
        <td class="mono">&lt; 3 mmol/L (often absent)</td>
        </tr>
        <tr>
        <td>Acidosis</td>
        <td><span class="badge badge-danger">Present</span></td>
        <td><span class="badge badge-ok">Minimal/absent</span></td>
        </tr>
        <tr>
        <td>Effective osmolality</td>
        <td>Variable</td>
        <td class="mono">&gt; 320 mOsm/kg</td>
        </tr>
        <tr>
        <td>Primary threat</td>
        <td>Ketoacidosis</td>
        <td>Hyperosmolality & dehydration</td>
        </tr>
        <tr>
        <td>Mortality</td>
        <td>&lt; 1%</td>
        <td><span class="badge badge-danger">15‚Äì20%</span></td>
        </tr>
        </tbody>
        </table>
        </div>

        <div class="card">
        <span class="pill">Management priorities (don‚Äôt mix these up)</span>

        <details open>
        <summary>Fluids</summary>
        <div class="content">
        <ul>
        <li><strong>DKA:</strong> Aggressive early fluids + insulin to stop ketogenesis.</li>
        <li><strong>HHS:</strong> <strong>Fluids first, slow correction</strong>; massive deficits (often 6‚Äì9 L).</li>
        </ul>
        </div>
        </details>

        <details open>
        <summary>Insulin</summary>
        <div class="content">
        <ul>
        <li><strong>DKA:</strong> Start early ‚Äì <span class="mono">0.1 units/kg/hr</span>.</li>
        <li><strong>HHS:</strong> <span class="badge badge-warn">Do NOT start early</span> unless ketones present or glucose not falling with fluids.
          If needed: <span class="mono">0.05 units/kg/hr</span>.</li>
        </ul>
        </div>
        </details>

        <details open>
        <summary>Potassium</summary>
        <div class="content">
        <ul>
        <li><strong>Both:</strong> Total body K‚Å∫ depleted.</li>
        <li><strong>Insulin ‚Üí intracellular shift</strong> ‚Üí dangerous hypokalemia.</li>
        <li>Target <span class="mono">4.0‚Äì5.5 mEq/L</span> in both conditions.</li>
        </ul>
        </div>
        </details>

        <details open>
        <summary>Osmolality</summary>
        <div class="content">
        <ul>
        <li><strong>DKA:</strong> Not the main treatment target.</li>
        <li><strong>HHS:</strong> <strong>Primary target</strong>; fall by <span class="mono">3‚Äì8 mOsm/kg/hr</span>.</li>
        <li>Rapid correction ‚Üí <span class="badge badge-danger">cerebral edema</span>.</li>
        </ul>
        </div>
        </details>
        </div>

        <div class="card">
        <span class="pill">Common pitfalls</span>
        <ul>
        <li>Starting insulin too early in HHS ‚Üí rapid osmolar shift.</li>
        <li>Stopping IV insulin before SQ overlap in DKA.</li>
        <li>Under‚Äëreplacing potassium once insulin starts.</li>
        <li>Ignoring thrombotic risk in HHS (LMWH is essential).</li>
        </ul>
        </div>

        <div class="card">
        <span class="pill">Quick formulas</span>
        <ul>
        <li><strong>Effective osmolality:</strong> <span class="mono">2 √ó Na + Glucose</span> (mmol/L)</li>
        <li><strong>Glucose conversion:</strong> <span class="mono">mmol/L √ó 18 ‚âà mg/dL</span></li>
        </ul>
        </div>
      </div>

  </div>
</main>

<footer>
  Offline-ready ‚Ä¢ Static HTML ‚Ä¢ US units first (UK units in brackets where useful)
</footer>

</body>
</html>
